Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

GenoImmune, a BGI Company, Completes Funding for NeoAntigen Cell Therapies

publication date: Aug 15, 2022

GenoImmune Therapeutics, a Wuhan company founded by China’s gene sequencing company, BGI, closed a funding round to support its immuno-cell therapy products. The company’s core technologies include its AI-driven neoantigen technology, a GMP cell preparation platform and mRNA tumor vaccines aimed at solid tumors including melanoma, lung cancer and colorectal cancer. Using its AI-based screening, GenoImmune can identify novel tumor antigens that are used in T-Cell and Neo-T cell therapies. In previous $15+ million rounds, the company attracted Hillhouse, ForeBright and Wuhan East-lake Venture Capital as investors. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital